ArticleCancer management and research2026
Early On-Treatment Expansion of Peripheral γδT Cells as a Noninvasive Biomarker of Response to Programmed Death-1 Inhibitor Therapy in Advanced Non-Small Cell Lung Cancer.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reliable biomarkers for predicting the response to programmed death-1 (PD-1) inhibitor therapy in advanced non-small cell lung cancer remain limited. Peripheral immune cell subsets, including gamma delta (γδ) T cells and T helper 17 (Th17) cells, may provide a noninvasive approach for monitoring systemic immune responses during immunotherapy; however, their clinical significance in patients with advanced non-small cell lung cancer remains incompletely understood. Methods: Sixty patients with advanced non-small cell lung cancer receiving nivolumab monotherapy were prospectively enrolled. Peripheral blood samples were collected at baseline and on day 28 after treatment initiation. Circulating γδ T cells and Th17 cells were quantified by flow cytometry, and serum tumor markers and cytokines were measured by enzyme-linked immunosorbent assay. Treatment response was evaluated using the iRECIST criteria. Correlation, multivariable logistic regression, and receiver operating characteristic (ROC) curve analyses were performed. Results: Responders exhibited significant increases in peripheral γδ T cells and Th17 cells after treatment, accompanied by reductions in serum tumor markers and immunosuppressive cytokines. Day-28 γδ T cell proportions were independently associated with treatment response and correlated inversely with serum tumor marker levels while showing positive correlations with Th17 cell frequencies and interleukin-2 concentrations. ROC analysis demonstrated that day-28 γδ T cells showed good discriminative performance for identifying responders (AUC = 0.915; sensitivity = 91.9%; specificity = 82.6%), whereas Th17 cells also demonstrated favorable predictive performance (AUC = 0.850). Conclusion: Early treatment-induced expansion of peripheral γδ T cells was associated with objective clinical response, reduced tumor burden, and favorable cytokine remodeling during PD-1 inhibitor therapy. Dynamic monitoring of peripheral γδ T cells may represent a promising noninvasive biomarker for early assessment of treatment response in advanced non-small cell lung cancer. These findings warrant validation in larger prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.